
NICE greenlights Consilient Health’s Elmiron for bladder pain syndrome
pharmafile | November 14, 2019 | News story | Sales and Marketing | NICE, consilient health, elmiron, pharma
NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of bladder pain syndrome (BPS), it has emerged, for patients whose condition has not responded to oral treatments and are not offered the drug in combination with bladder instillations.
The decision was reached as the two parties agreed to a patient access scheme to make the drug available to NHS patients.
In regards to the decision, BPS is defined as chronic pain, discomfort or pressure in the pelvic region combined with at least one other urinary symptom.
“This is a condition with a significant unmet clinical need and the company is delighted that Elmiron has been recommended for the treatment of IC/BPS,” commented Amanda Paxon, Country Manager, Pharmaceuticals at Consilient Health UK.
Susannah Fraser, Communication and Media Manager at Bladder Health UK, also remarked on the news: “BPS is a debilitating condition and has a considerable detrimental impact on the individual’s lifestyle, ability to work, emotional health and relationships. Their quality of life is hugely compromised. For individuals to be able to access Elmiron on the NHS is really good news.”
Matt Fellows
Related Content

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …






